Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity

Area of Science:

• Hepatotoxicity research
• Molecular toxicology
• Cellular signaling pathways

Background:

• Troglitazone (TRO) is a withdrawn drug known for causing liver damage.
• Understanding the molecular mechanisms of drug-induced cytotoxicity is crucial for drug safety.
• HepG2 cells are a widely used model for studying liver function and toxicity.

Purpose of the Study:

• To investigate the specific molecular changes in HepG2 cells exposed to Troglitazone (TRO).
• To identify proteins involved in TRO-induced cytotoxicity.
• To elucidate the role of post-translational modifications in TRO toxicity.

Main Methods:

• HepG2 cells were treated with varying concentrations of TRO and rosiglitazone (RSG).
• Proteomic analysis using two-dimensional electrophoresis and silver staining identified protein changes.
• Amino acid sequencing identified specific proteins, followed by mRNA and protein expression analysis.
• Caspase inhibition was used to explore the role of apoptosis.

Main Results:

• A specific protein spot, identified as ribosomal protein P0 (P0), appeared at cytotoxic concentrations of TRO (50 and 75 microM).
• P0 was dephosphorylated in a concentration- and time-dependent manner with TRO exposure, independent of protein/mRNA induction.
• Caspase inhibition did not prevent P0 dephosphorylation or fully reverse cytotoxicity.
• Rosiglitazone (RSG) did not induce these changes at any concentration.

Conclusions:

• Dephosphorylation of ribosomal protein P0 (P0) is a key post-translational modification associated with Troglitazone (TRO)-induced cytotoxicity in HepG2 cells.
• This specific P0 modification is distinct from the effects of rosiglitazone (RSG).
• The findings suggest P0 dephosphorylation as a potential biomarker or therapeutic target for TRO-related liver injury.